Slate Medicines’ antibody drug is designed to block PACAP, a protein associated with migraines. The Phase 1-ready asset was licensed from China-based DartsBio Pharmaceuticals.
The post Headache Startup Slate Medicines Lands $130M to Bring Novel Migraine Drug Into the Clinic appeared first on MedCity News.
President Trump’s second choice for U.S. surgeon general has set off a wave of infighting within the Make America Healthy Again (MAHA) movement. Casey Means […]
That is the title of a paper I published today in Journal of Market Access & Health Policy with co-authors […]
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The HHS on Thursday released […]